Toxoplasma gondii and related human parasites contain an essential plastid 16 organelle called the apicoplast. Clinically-used antibiotics and other inhibitors that 17 disrupt apicoplast biogenesis cause a mysterious "delayed-death" phenotype, in which 18 parasite growth is unaffected during the first lytic cycle of inhibitor treatment but is 19 severely inhibited in the second lytic cycle even after drug removal. Critical to 20 understanding the complex downstream cellular effects of these drug classes is the timing 21 of apicoplast loss during inhibitor treatment and how it relates to this peculiar growth 22 phenotype. Here we show that, upon treatment with diverse classes of apicoplast 23 highlight key differences in "delayed-death" inhibitors between T. gondii and 33
inhibitors, newly-replicated T. gondii parasites in the first lytic cycle initially form 24 apicoplasts with defects in protein import or genome replication and eventually fail to 25 inherit the apicoplast altogether. Despite the accumulation of parasites with defective or 26 missing apicoplasts, growth is unaffected during the first lytic cycle, as previously 27 observed. Strikingly, concomitant inhibition of host cell isoprenoid biosynthesis results in 28 growth inhibition in the first lytic cycle and unmasks the apicoplast defects. These results 29 suggest that defects in and even complete loss of the apicoplast in T. gondii are partially 30 rescued by scavenging of host cell metabolites leading to death that is delayed. Our 31 findings uncover host cell interactions that can alleviate apicoplast inhibition and 32
Introduction 36
The Apicomplexan phylum contains human and animal parasites including 37
Toxoplasma gondii, which cause opportunistic infections, and Plasmodium spp., which 38 cause malaria. These parasites contain an essential plastid organelle called the apicoplast 39 that is derived from secondary endosymbiosis of a red alga (1-3). While the apicoplast is 40 no longer photosynthetic, it houses essential pathways for biosynthesis of fatty acids, 41 heme, iron-sulfur clusters, and isoprenoid precursors (4-6). Apicoplast ribosome 42 inhibitors, such as clindamycin and doxycycline, are used clinically for treatment of acute 43 toxoplasmosis and malaria chemoprophylaxis, respectively (7, 8) . In both T. gondii 44 tachyzoites and blood-stage P. falciparum, these inhibitors cause a peculiar "delayed-45 death" phenotype in vitro: Treatment with inhibitors during the first lytic cycle has no 46 effect on parasite replication, egress of daughter parasites from the first host cell, or 47 reinfection of new host cells. However, parasites subsequently fail to replicate in the 48 second lytic cycle, even if the inhibitor is removed (9) (10) (11) . In addition to structurally-49 diverse antibiotics targeting the prokaryotic ribosome, inhibitors of DNA gyrase 50 (ciprofloxacin) and the apicoplast membrane metalloprotease FtsH1 (actinonin) also 51 cause delayed death in T. gondii, indicating that drug properties do not account for the 52 delayed growth inhibition and that delayed death is likely a result of complex 53 downstream cellular effects of apicoplast inhibitors (9, 10, 12, 13) . 54
Each of these apicoplast inhibitors causes defects in apicoplast biogenesis-its 55 growth, division, and inheritance, leading to the formation of T. gondii parasites that are 56 missing the apicoplast entirely (10, 12, 13) . It is therefore surprising that these drug-57 treated parasites replicate to wild-type levels in the first lytic cycle during inhibitor 58 treatment, as defects in or loss of the apicoplast should render parasites unable to produce 59 essential apicoplast-derived metabolites (14). How parasites are able to compensate for 60 this loss during the first lytic cycle remains poorly understood. Of note, growth kinetics 61 resembling delayed death have also been observed for inhibitors that block apicoplast 62 metabolic function and genetic disruption of proteins required for apicoplast biogenesis 63 or metabolism, suggesting that inhibiting production of essential apicoplast metabolites 64 may be the common perturbation leading to delayed death in T. gondii (5, (15) (16) (17) (18) . 65
A number of models have been proposed to explain how apicoplast defects lead to 66 delayed death. One model proposes that apicoplast metabolites are only required for the 67 successful establishment of a parasitophorous vacuole (PV) but are dispensable during 68 intravacuolar replication (9). Another model proposes that growth of parasites with 69 defective apicoplasts during the first lytic cycle is supported by sister parasites with 70 functioning apicoplasts in the same vacuole (19). These models, however, are 71 inconsistent with experiments in which clindamycin-treated parasites were manually 72 released from the host cell prior to completion of the first lytic cycle, separated from 73 sister parasites, and allowed to establish a new infection. These drug-treated, 74 prematurely-lysed parasites were able to establish a new PV and replicate, albeit at 75 reduced rates that depended on the duration of drug treatment and number of replications 76 in the previous vacuole (9). These parasites also eventually fail to replicate in the third or, 77 with continued manual release, later lytic cycles (9), suggesting that the "delay" in 78 growth inhibition is not strictly tied to lytic cycles. Thus neither of the proposed models 79 is sufficient to explain the delayed-death phenotype. 80
Several key questions remain. First, what is the timing of apicoplast biogenesis 81 defects and loss upon treatment with apicoplast inhibitors? Apicoplast loss is an 82 important downstream cellular consequence of these inhibitors but has not been 83 quantified during a full lytic cycle. Second, do apicoplast inhibitors with distinct 84 molecular targets lead to different rates of apicoplast loss? While the literature would 85 suggest similar phenotypes between diverse classes of apicoplast inhibitors, this has yet 86 to be confirmed with a side-by-side comparison. Third, what is the role of the host cell in 87 delayed death? We hypothesize that, since T. gondii replicates in a metabolically active 88 host cell, host metabolites may compensate for apicoplast inhibition. Fourth, how do the 89 downstream cellular effects of apicoplast inhibition differ between T. gondii and P. 90 falciparum? Their distinct replication cycles, differences in their host cell metabolic 91 activity, and the overlapping but distinct inhibitor classes that cause delayed death in 92 these parasites suggest different mechanisms underlie the seemingly similar delayed 93 growth kinetics. 94
To address these questions, we validated an apicoplast marker to monitor 95 apicoplast biogenesis defects and loss and show that multiple classes of apicoplast 96 inhibitors cause gradual accumulation of parasites with disrupted or missing apicoplasts. 97
Interestingly, the delayed-death growth kinetics caused by these apicoplast inhibitors is 98 modulated by an inhibitor of host cell isoprenoid biosynthesis. These results clarify the 99 complex downstream cellular effects of apicoplast inhibition in T. gondii and their 100 similarities and differences to that in P. falciparum. 101
102
Results 103
Apicoplast inhibitors cause reduced or absent FNR-RFP, an apicoplast marker. 104
We selected three inhibitors that are well-documented to cause delayed-death in 105
T. gondii and have strong evidence for their target in the apicoplast: actinonin (membrane 106 metalloprotease FtsH1), clindamycin (ribosome), and ciprofloxacin (DNA gyrase) (5, 10, 107 12, 13, 20) . During treatment with these compounds, the apicoplast had been previously 108 observed by microscopy of T. gondii RH parasites expressing an apicoplast-targeted 109 ferredoxin NADP+ reductase fused to red fluorescence protein (FNR-RFP) (12, 18, 21-110 24) . In these experiments, treatment with apicoplast inhibitors leads to vacuoles with 111 some parasites missing FNR-RFP fluorescence (10, 12, 18) . While these studies 112
suggested that the inhibitors lead to disruption of apicoplast biogenesis, it was unclear 113 how exactly FNR-RFP fluorescence corresponded to apicoplast presence. Furthermore, 114 since these studies used microscopy, they could only count apicoplasts in vacuoles 115 containing <8 parasites, corresponding to no more than 3 replications out of >6 total 116 replications during the lytic cycle (10, 12, 18) . To clarify these initial observations, we 117 sought to develop a quantitative method to monitor apicoplast loss through a full lytic 118 cycle. Because microscopy of large vacuoles with 8+ parasites is difficult, we used flow 119 cytometry to count and quantify the FNR-RFP fluorescence of individual extracellular 120 parasites after host cell egress. 121
We compared FNR-RFP fluorescence with the presence of the apicoplast genome, 122 a known apicoplast marker. Briefly, parasites were treated with actinonin, clindamycin, 123 or ciprofloxacin for a single lytic cycle. After natural egress from the first lytic cycle, 124 egressed parasites were collected and their FNR-RFP fluorescence was quantified by 125 flow cytometry ( Fig 1A-B ). While untreated parasites retained high levels of FNR-RFP 126 fluorescence, treatment with each apicoplast inhibitor generated two populations of 127 parasites: one devoid of FNR-RFP fluorescence [FNR-RFP(-)] and one in which FNR-128 RFP was detectable but with a mean fluorescence intensity 25-75% less than that of the 129 untreated population [FNR-RFP(reduced)]. We sorted these two populations and 130 quantified their apicoplast:nuclear genome ratio by qPCR ( Fig 1C) . The apicoplast 131 genome was at reduced levels compared to untreated parasites but still detectable in 132 FNR-RFP(reduced) parasites. In contrast, the apicoplast genome was below the detection 133 limit in FNR-RFP(-) parasites, consistent with loss of the apicoplast in FNR-RFP(-) 134 parasites. These results validate the use of the FNR-RFP fluorescence as a marker for 135 apicoplast presence. It also suggests that, while the FNR-RFP(reduced) cells still contain 136 the apicoplast, the apicoplast is defective given the reduced levels of FNR-RFP 137 fluorescence, lower apicoplast genome copy number, and failure of both populations to 138 grow in the next lytic cycle (10, 12, 13) . 139 140 Apicoplast loss occurs gradually during the first lytic cycle. 141
During the T. gondii lytic cycle, a single parasite undergoes >6 synchronous 142 rounds of binary division forming >64 daughter parasites within a vacuole in the host cell 143 (25). Apicoplast growth, division, and inheritance is coordinated with parasite replication 144 leading to exactly one apicoplast per parasite (26). Because parasites grow to wild-type 145 levels during the first lytic cycle during treatment, we were surprised to find that the large 146 majority of parasites had either disrupted or undetectable apicoplasts at this time point 147
( Fig 1A-C) . We therefore further characterized the timing of apicoplast disruption during 148 the first lytic cycle. 149
T. gondii parasites were treated with apicoplast biogenesis inhibitors and parasites 150 were harvested after 6, 12, 24, 36, or 48 hours of treatment (Fig 2A) . At each time point, 151
we manually released parasites from host cells and assessed apicoplast status based on (1) 152 apicoplast genome levels; (2) observed is a slight reduction in the levels of the apicoplast genome for parasites treated 159 with actinonin and ciprofloxacin ( Fig 2B) . After 24 hours, parasites have completed 3-4 160 divisions and reductions in levels of the apicoplast genome are detected for all apicoplast 161 inhibitors ( Fig 2B) . Also at this time point, other apicoplast defects start to appear. We 162 observed that drug-treated parasites begin to accumulate full-length Cpn60 (FL) ( Fig 2C) , 163 indicating a defect in apicoplast protein import. The FNR-RFP fluorescence of parasites 164 expressing measurable FNR-RFP, starts to dim for parasites treated with actinonin and 165 clindamycin ( Fig 2D) . Lastly, FNR-RFP(-) parasites start to emerge in samples treated 166 with actinonin ( Fig 2E) . These defects continue to accumulate for all drug-treated 167 parasites. By 48 hours, T. gondii has completed 6-8 divisions and egressed from the host 168 cell. At this time point, the apicoplast genome levels are reduced to 8-22% ( Fig 2B) , the 169 proportion of (FL) TgCpn60 has increased ( Fig 2C) , the mean levels of FNR-RFP 170 fluorescence in the FNR-RFP(reduced) population is 25-50%, and 25-50% of parasites 171 lose FNR-RFP fluorescence all together (FNR-RFP(-)) compared to untreated control 172 parasites. Overall, we observe that T. gondii parasites treated with apicoplast inhibitors 173 exhibit apicoplast biogenesis defects as early as the 2 nd parasite replication and the 174 severity of these defects worsen throughout the first lytic cycle of treatment, despite 175 normal growth. Because T. gondii parasites treated with apicoplast inhibitors accumulate 180 apicoplast biogenesis defects and lose their apicoplast long before growth inhibition is 181 observed (Fig 2D-E) , we sought to determine whether the scavenging of host cell 182 metabolites can compensate for the loss of one or more apicoplast metabolic functions. 183
Isoprenoid biosynthesis is an essential function of the apicoplast (5, 6), and scavenging of 184 host cell isoprenoids by T. gondii has already been shown (28). Therefore parasites were 185 co-treated with apicoplast inhibitors and atorvastatin, a specific inhibitor of host cell 186 isoprenoid biosynthesis. As seen previously, treatment with 13 µM atorvastatin alone did 187 not affect parasite growth, suggesting that in the presence of an intact apicoplast host cell 188 isoprenoid biosynthesis is not essential (Fig 3, Supplemental Fig 1) (28) . However, unlike 189 atorvastatin or apicoplast inhibitors alone, the combination of atorvastatin with actinonin, 190 clindamycin, or ciprofloxacin caused parasite growth inhibition within the first lytic cycle 191 (Fig 3, Supplemental Fig 1) . Instead of growing to wild-type levels during a full 48-hour 192 lytic cycle, growth defects are detectable starting 24 hours after treatment (Fig 3,  193 Supplemental Fig 1) . After 48 hours, parasites co-treated with atorvastatin and apicoplast 194 inhibitors show 30-50% growth compared to parasites treated with apicoplast inhibitors 195 only (Fig 3) . The minimum inhibitory concentration (MIC) of apicoplast inhibitors for 196 growth inhibition was similar in the presence and absence of atorvastatin, indicating that 197 atorvastatin's potential effect on host cell permeability did not result in off-target effects 198 (MIC = 20 µM actinonin +/-atorvastatin; MIC = 4 nM clindamycin +/-atorvastatin). 199
Rather, the altered kinetics of growth inhibition suggest that, with loss of apicoplast 200 function, parasites either require host isoprenoid biosynthesis after 24 hours or deplete 201 host isoprenoid reservoirs after 24 hours. We favor the former model since pretreatment 202 of host cells with atorvastatin for 24 hours prior to infection with T. gondii showed 203 similar results ( Supplementary Figure 2) . 204 205
Discussion 206
Our findings suggest the following model for the downstream cellular effects of 207 apicoplast inhibitors in T. gondii. First, several classes of apicoplast inhibitors cause 208 accumulation of apicoplast biogenesis defects and eventual apicoplast loss. We detect 209 these defects beginning as early as the 2 nd parasite replication in the first lytic cycle, 210 preceding growth defects in the second lytic cycle. 211
Second, apicoplast biogenesis defects disrupt its biosynthetic functions important 212 both for intravacuolar growth and likely establishment of infection in new host cells. This 213 model predicts that direct inhibition of apicoplast biosynthetic pathways, without 214 disrupting its biogenesis, will also cause delayed death, consistent with prior observations 215 in the literature (16, 17) . 216
Third, scavenging of host cell metabolites in the first lytic cycle can substitute for 217 metabolites normally biosynthesized in the apicoplast. We specifically tested the 218 scavenging of host cell isoprenoids, which was required 24 hours into the first lytic cycle. 219
Host fatty acids and heme may also compensate for loss of these apicoplast biosynthetic 220 functions, although we were unable to directly test these pathways given the lack of 221 specific inhibitors. Overall, we propose that host cell metabolites support the growth of T. 222 gondii during the first lytic cycle of apicoplast inhibition. Our results add to a growing 223 body of work indicating that access to host metabolites regulates the essentiality of 224 parasite metabolic pathways and the organelles that provide them (28-32). 225
Finally, host cell metabolites cannot compensate for the apicoplast indefinitely, 226 since parasites treated with apicoplast inhibitors ultimately fail to replicate in later lytic 227 cycles. It is possible that metabolites sourced from the apicoplast are required at the 228 beginning of the lytic cycle for PV formation and host cell remodeling. If this is true, then 229 drug-treated parasites prematurely lysed from host cells may continue to grow in 230 subsequent lytic cycles because the apicoplast is still partially functional at these early 231 time points. Alternatively, a combination of host cell scavenging and accrued apicoplast 232 metabolites may be sufficient during the first lytic cell but ultimately become depleted in 233 subsequent lytic cycles. More experiments are required to differentiate between these 234 scenarios, and ultimately reveal the essential products of the T. gondii apicoplast. 235
These downstream cellular effects of apicoplast biogenesis inhibitors in T. gondii 236 differ from the known effects in P. falciparum in significant ways. First, we show that T. 237 gondii parasites lacking apicoplasts accumulate over multiple parasite replications during 238 the first lytic cycle. In contrast, blood-stage P. falciparum only undergoes a single round 239 of parasite replication during each host lytic cycle, and apicoplast biogenesis is largely 240 unaffected by treatment with apicoplast translation inhibitors during the first lytic cycle (a 241 small reduction in apicoplast genome copies is sometimes observed) (11, 33) . Second, we 242
show that T. gondii parasites lacking apicoplasts are viable during the first lytic cycle, 243 and apicoplast loss and parasite growth inhibition are temporally separated. In contrast, 244 P. falciparum growth inhibition occurs concurrently with apicoplast biogenesis defects in 245 the second lytic cycle most likely because apicoplast loss cannot be overcome by 246 scavenging of host cell metabolites (6, 11) . We suspect this is due to the different 247 metabolic activities of their respective host cells: while P. falciparum grows in relatively 248
inert red blood cells, T. gondii makes its home in metabolically-active host cells. Third, 249 while all known apicoplast inhibitors cause delayed death in T. gondii, only the subset of 250 apicoplast inhibitors that disrupt apicoplast genome expression cause delayed death in P. 251 falciparum (12). The common defect leading to delayed death in T. gondii appears to be 252 loss of apicoplast metabolic function, while the common defect in P. falciparum delayed 253 death is loss of apicoplast genome expression. While it is possible that different 254 molecular targets account for these different inhibitor phenotypes, all apicoplast 255 inhibitors used in this study have strong evidence for the same target in both organisms 256 (10, 12, 13, 33) . Instead, these different downstream cellular effects of apicoplast 257 inhibitors likely reflect the different biology of the parasites and their dependence on 258 apicoplast metabolic function. (Invitrogen) and transferred to a nitrocellulose membrane. After blocking, membranes 321 were probed with 1:5000 polyclonal rabbit anti-TgCpn60 (gift from Boris Striepen, 322
University of Pennsylvania) and 1:10,000 IRDye 800RD donkey anti-rabbit (LiCor 323
Bioscience, Lincoln, NE). Fluorescence antibody-bound proteins were detected with 324
Odyssey Imager (LiCor Biosciences). Immunoblots were performed 2 times. The funders had no role in study design, data collection and interpretation, or the decision 342 to submit the work for publication. Schematic of experimental procedure. T. gondii parasites are allowed to infect host cells 366 and grow in the presence or absence of apicoplast inhibitors (blue = untreated, red = 367 actinonin, green = clindamycin, purple = ciprofloxacin). At 6, 12, 24, 36, or 48 hours, 368 parasites are manually released from host cells. Because host cell lysis occurs between 36 369 and 48 hours, parasites analyzed at these time points may reflect growth in the second 370 
